Technology ID
TAB-3519
Remodelins, a New Class of Compounds to Prevent or Treat Cancer Metastasis or Glaucoma
E-Numbers
E-179-2018-0
Lead Inventor
Luci, Diane (NCATS)
Co-Inventors
Solway, Julian (University of Chicago Medical Center)
Park, ChanYoung (Harvard University School of Public Health)
Fredberg, Jeffery (Harvard University School of Public Health)
McCormick, David (Illinois Institute of Technology (IIT))
Maloney, David (Inspyr Therapeutics, Inc (ITRI))
Dulin, Nickolai (University of Chicago)
Krishnan, Ramaswamy (Beth Israel Deaconess Medical Center)
Chen, Bohao (University of Chicago)
Wang, Jiaolong (University of Chicago)
Lavoie, Tera (University of Chicago)
Gurvich, Vadim (University of Minnesota)
Byrn, Stephen (Purdue University)
Muzzio, Miguel (Illinois Institute of Technology (IIT))
White, Stephen (University of Chicago)
Laxman, Bharathi (University of Chicago)
He, Tong-Chuan (University of Chicago)
Conzen, Suzanne (University of Chicago)
Rosner, Marsha (University of Chicago)
Applications
Therapeutics
Therapeutic Areas
Ophthalmology
Oncology
Infectious Disease
Endocrinology
Dental
Cardiology
Lead IC
NCATS
ICs
NCATS
This technology includes a series of small molecule organic compounds, called remodelins, that are synthetic derivative analogs of a parent compound discovered by screening of a Chembridge library. The novel synthetic derivative analogs were generated through multiple iterations of compounds directed by in vitro experiments. The invention also includes use of these or related molecules to treat cancer and/or glaucoma.
Commercial Applications
Further clinical work with the remodelins could establish these compounds for the inhibition or treatment of cancer metastasis and/or glaucoma.
Competitive Advantages
This invention is a new class of compounds for the treatment of cancer and/or glaucoma.
Licensing Contact: